🧫 Experiment Protocol
Clinicalproposed
SUMMARY
# Peroxisome Dysfunction Validation in Parkinson's Disease
## Background and Rationale
This clinical investigation tests the hypothesis that peroxisome dysfunction represents an upstream pathogenic driver in Parkinson's disease, contributing to oxidative stress, lipid metabolism disruption, and neuroinflammation. The study employs a multi-modal approach combining advanced metabolomics, proteomics, and functional cellular assays to characterize peroxisome-related biomarkers in PD patients. Partic
METHODOLOGY NOTES
**Phase 1: Participant Recruitment and Baseline Assessment (Months 1-3)**
• Recruit 150 PD patients (Hoehn & Yahr stages 1-3) from movement disorder clinics
• Recruit 75 age-matched healthy controls
• Obtain informed consent and perform comprehensive neurological evaluation
• Collect medical history, medication records, and family history
• Perform MDS-UPDRS Parts I-IV assessments
• Collect baseline blood samples (50mL) and CSF samples (10mL) via lumbar puncture
**Phase 2: Peroxisome Function Assessment (Months 2-4)**
• Measure plasma very long-chain fatty acids (VLCFA) using GC-MS
• Quantify pristanic and phytanic acid levels via LC-MS/MS
• Assess bile acid synthesis intermediates (DHCA, THCA) in plasma
• Evaluate catalase activity in peripheral blood mononuclear cells
• Measure plasmalogen levels (16:0, 18:0, 18:1) in erythrocyte membranes
• Quantify peroxisomal β-oxidation capacity using cultured skin fibroblasts
**Phase 3: Alpha-Synuclein and Inflammatory Markers (Months 3-5)**
•